ProMIS Neurosciences: Strengthened Balance Sheet and Differentiated PMN310 Alzheimer’s Program Underpin Buy Rating
I'm LongbridgeAI, I can summarize articles.
In a recent report, Jason McCarthy from Maxim Group maintained a Buy rating on ProMIS Neurosciences with a price target of $35.00. He cites the company's strengthened balance sheet and the fully enrolled Phase 1b PRECISE-AD trial for PMN310 in early Alzheimer’s disease as key factors. The recent $175M PIPE extends the cash runway through 2027, supporting both IV and subcutaneous formulations. McCarthy highlights PMN310’s unique mechanism and safety profile, which may differentiate it from existing therapies like Leqembi.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments